Status:
COMPLETED
Canadian Alliance for Healthy Hearts and Minds
Lead Sponsor:
Montreal Heart Institute
Conditions:
Cardiovascular Diseases
Eligibility:
All Genders
35-69 years
Brief Summary
The Cardiac, Vascular and Cognitive Dysfunction (CVCD) Alliance will be a prospective, multi-ethnic cohort study in healthy Canadian individuals between 35 and 69, looking at contextual risk factors a...
Detailed Description
Cardiac, vascular, and cognitive dysfunction have a strong impact on the quality of life, longevity and health care costs, in Canada and globally. Cardiovascular risk factors account for up to half of...
Eligibility Criteria
Inclusion
- Informed Consent Form (ICF) was discussed, understood and signed by the participant
- Participant is between ages 35 and 69 (inclusively) at time of screening
- The participant is willing to undergo an MRI scan and all other required study procedures
Exclusion
- Participant has a known acute disease or condition that is considered serious in the investigator's opinion
- Participant is claustrophobic and/or is known to suffer from moderate to severe anxiety during MRI scans or similar procedures
- Participant is obese and/or exceeds equipment weight limit and/or circumference of the MRI portal at this of screening
- Participant has any kind of metallic device that would contra-indicate Magnetic Resonance Imaging (MRI) (e.g. pacemakers, defibrillator, vascular clips, drug pumps, implant(s), or any other foreign bodies)
- Participant has an extensive tattoo covering a large part of their chest or head
- Female participants that are currently pregnant (confirmed or uncertain).
- Participants receiving Gadovist® only - Female participants that are currently breastfeeding.
- Participants receiving Gadovist® only - Participant has a known hypersensitivity to gadolinium-based contrast agents
- Participants receiving Gadovist® only - Participant has a known allergy or severe reaction to any contrast agent typically used in MRI procedures
- Participants receiving Gadovist® only - Participant has known renal or hepatic impairment of any intensity or any other kidney/liver disease or has recently undergone kidney/liver transplant
- Participants receiving Gadovist® only - Participant has a known glomerular filtration rate (eGFR or GFR) of 30 mL/min or less
- Participants receiving Gadovist® only - Participant has taken part in a clinical research study or clinical study within 30 days prior to enrollment in this study, and/or received contrast agent within 72 hours prior to the study MRI
Key Trial Info
Start Date :
November 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2019
Estimated Enrollment :
7900 Patients enrolled
Trial Details
Trial ID
NCT02220582
Start Date
November 1 2013
End Date
April 1 2019
Last Update
February 21 2020
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Seaman Family MR Research Center
Calgary, Alberta, Canada, T2N2T9
2
University of Calgary
Calgary, Alberta, Canada, T2N4N1
3
St Paul's Hospital
Vancouver, British Columbia, Canada, V6Z1Y6
4
QEII Health Sciences Center
Halifax, Nova Scotia, Canada, B3H3A7